Mon, July 18, 2022

Kostas Biliouris Maintained (VERV) at Buy with Increased Target to $62 on, Jul 18th, 2022

Kostas Biliouris of BMO Capital, Maintained "Verve Therapeutics, Inc." (VERV) at Buy with Increased Target from $48 to $62 on, Jul 18th, 2022.

Kostas, nor any peers, have made any analyst calls on VERV in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30